{"id":2801,"date":"2011-11-20T00:00:00","date_gmt":"2011-11-20T05:00:00","guid":{"rendered":"https:\/\/beta.cancea.ca\/index.php\/2017\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/"},"modified":"2022-11-21T16:31:56","modified_gmt":"2022-11-21T21:31:56","slug":"life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038","status":"publish","type":"post","link":"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/","title":{"rendered":"Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038"},"content":{"rendered":"

The goals of the current report are: (1) to estimate the life and economic burden in Canada attributed to the incidence of three nosocomial infections; and (2) to demonstrate the value proposition significance if this burden can be reduced by systematic interventions to improve strategies for nosocomial infections control and prevention. The stated goals of the report are achieved by applying a systematic discrete eventsimulation analysisto the life and economic impacts of methicillin\u2010resistant Staphylococcus aureus (MRSA), clostridium difficile (c. difficile) and vancomycin\u2010resistant enterococci (VRE) upon the Canadian population and economy from 2009 to 2038.<\/p>\n

<\/p>\n

Further, three intervention scenarios are considered by the analysis. The intervention scenarios are generated under the assumptionsthat the current responsesto manage nosocomial infections will improve between 2009 and 2038 as a result of a nation\u2010wide strategy for nosocomial infection control and prevention. It is assumed that implementation of the strategy over a 30\u2010year period will result in a reduction in the incidence of the nosocomial infections as well as the attributed mortality. Each intervention scenario estimates a hypothetical reduction in economic burden forthe society and the Government.<\/p>\n

The following intervention scenarios are considered by this study:<\/p>\n

\u2022 Scenario 1: Lower Impact. The strategy will result in a 10% reduction in the incidence of the considered nosocomial infections over the 30\u2010year period;
\n\u2022 Scenario 2: Intermediate Impact. The strategy will result in a 20% reduction in the incidence of the considered nosocomial infections over the 30\u2010year period; and
\n\u2022 Scenario 3: Higher Impact. The strategy will result in a 30% reduction in the incidence of the considered nosocomial infections over the 30\u2010year period.<\/p>\n

Implementation of each intervention scenario is assumed to begin in 2009 and reach its intervention goal by 2019. The simulation platform used for this analysis is a \u2018discrete event simulation\u2019 decision analytic policy platform that incorporates the design of peer reviewed empirical models (e.g. clinical trials) and empirical data (eg. historical and surveillance data, health costs) into modulized discrete event simulations. This simulation platform is designed to conduct modern multidisciplinary quantitative modeling that supports evidence\u2010based performance evaluation and tracking of health care initiatives.<\/p>\n

\n
\n
Download the Report<\/span><\/span> <\/a><\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The goals of the current report are: (1) to estimate the life and economic burden in Canada attributed to the incidence of three nosocomial infections; and (2) to demonstrate the value proposition significance if this burden can be reduced by systematic interventions to improve strategies for nosocomial infections control and prevention. The stated goals of …<\/p>\n

Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038<\/span> Read More »<\/a><\/p>\n","protected":false},"author":1,"featured_media":2802,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-global-header-display":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":""},"categories":[112,109,136,162,177,135,108,111,137,97],"tags":[],"acf":[],"yoast_head":"\nLife and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038 - Canadian Centre for Economic Analysis<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038 - Canadian Centre for Economic Analysis\" \/>\n<meta property=\"og:description\" content=\"The goals of the current report are: (1) to estimate the life and economic burden in Canada attributed to the incidence of three nosocomial infections; and (2) to demonstrate the value proposition significance if this burden can be reduced by systematic interventions to improve strategies for nosocomial infections control and prevention. The stated goals of … Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038 Read More »\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Centre for Economic Analysis\" \/>\n<meta property=\"article:published_time\" content=\"2011-11-20T05:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-21T21:31:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancea.ca\/wp-content\/uploads\/2022\/11\/report_56.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1700\" \/>\n\t<meta property=\"og:image:height\" content=\"2200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"david\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"david\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/\"},\"author\":{\"name\":\"david\",\"@id\":\"https:\/\/www.cancea.ca\/#\/schema\/person\/fb2e19aa9612d9bd6408e701abf68b0e\"},\"headline\":\"Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038\",\"datePublished\":\"2011-11-20T05:00:00+00:00\",\"dateModified\":\"2022-11-21T21:31:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/\"},\"wordCount\":357,\"publisher\":{\"@id\":\"https:\/\/www.cancea.ca\/#organization\"},\"articleSection\":[\"Business Cases, Impact Evaluations, And Appraisals\",\"Canada\",\"Forecasting, Scenarios And Sensitivities\",\"Health\",\"Infectious Disease\",\"Influence Via Specialized Reports\",\"Region\",\"Service\",\"Strategic Advice And Insights Generation\",\"Topic\"],\"inLanguage\":\"en-CA\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/\",\"url\":\"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/\",\"name\":\"Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038 - Canadian Centre for Economic Analysis\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancea.ca\/#website\"},\"datePublished\":\"2011-11-20T05:00:00+00:00\",\"dateModified\":\"2022-11-21T21:31:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancea.ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancea.ca\/#website\",\"url\":\"https:\/\/www.cancea.ca\/\",\"name\":\"Canadian Centre for Economic Analysis\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.cancea.ca\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancea.ca\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancea.ca\/#organization\",\"name\":\"Canadian Centre for Economic Analysis\",\"url\":\"https:\/\/www.cancea.ca\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/www.cancea.ca\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancea.ca\/wp-content\/uploads\/2022\/11\/CANCEA-Logo.png\",\"contentUrl\":\"https:\/\/www.cancea.ca\/wp-content\/uploads\/2022\/11\/CANCEA-Logo.png\",\"width\":3679,\"height\":625,\"caption\":\"Canadian Centre for Economic Analysis\"},\"image\":{\"@id\":\"https:\/\/www.cancea.ca\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.cancea.ca\/#\/schema\/person\/fb2e19aa9612d9bd6408e701abf68b0e\",\"name\":\"david\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-CA\",\"@id\":\"https:\/\/www.cancea.ca\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4ac119c7984ffc5e319b73989f8b986a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4ac119c7984ffc5e319b73989f8b986a?s=96&d=mm&r=g\",\"caption\":\"david\"},\"sameAs\":[\"https:\/\/beta.cancea.ca\"],\"url\":\"https:\/\/www.cancea.ca\/index.php\/author\/david\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038 - Canadian Centre for Economic Analysis","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/","og_locale":"en_US","og_type":"article","og_title":"Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038 - Canadian Centre for Economic Analysis","og_description":"The goals of the current report are: (1) to estimate the life and economic burden in Canada attributed to the incidence of three nosocomial infections; and (2) to demonstrate the value proposition significance if this burden can be reduced by systematic interventions to improve strategies for nosocomial infections control and prevention. The stated goals of … Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038 Read More »","og_url":"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/","og_site_name":"Canadian Centre for Economic Analysis","article_published_time":"2011-11-20T05:00:00+00:00","article_modified_time":"2022-11-21T21:31:56+00:00","og_image":[{"width":1700,"height":2200,"url":"https:\/\/www.cancea.ca\/wp-content\/uploads\/2022\/11\/report_56.jpg","type":"image\/jpeg"}],"author":"david","twitter_card":"summary_large_image","twitter_misc":{"Written by":"david","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/#article","isPartOf":{"@id":"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/"},"author":{"name":"david","@id":"https:\/\/www.cancea.ca\/#\/schema\/person\/fb2e19aa9612d9bd6408e701abf68b0e"},"headline":"Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038","datePublished":"2011-11-20T05:00:00+00:00","dateModified":"2022-11-21T21:31:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/"},"wordCount":357,"publisher":{"@id":"https:\/\/www.cancea.ca\/#organization"},"articleSection":["Business Cases, Impact Evaluations, And Appraisals","Canada","Forecasting, Scenarios And Sensitivities","Health","Infectious Disease","Influence Via Specialized Reports","Region","Service","Strategic Advice And Insights Generation","Topic"],"inLanguage":"en-CA"},{"@type":"WebPage","@id":"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/","url":"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/","name":"Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038 - Canadian Centre for Economic Analysis","isPartOf":{"@id":"https:\/\/www.cancea.ca\/#website"},"datePublished":"2011-11-20T05:00:00+00:00","dateModified":"2022-11-21T21:31:56+00:00","breadcrumb":{"@id":"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancea.ca\/index.php\/2011\/11\/20\/life-and-economic-impacts-of-nosocomial-methicillin-resistant-staphylococcus-aureus-clostridium-difficile-and-vancomycin-resistant-enterococci-in-canada-2009-to-2038\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancea.ca\/"},{"@type":"ListItem","position":2,"name":"Life and economic impacts of nosocomial methicillin-resistant staphylococcus aureus, clostridium difficile and vancomycin-resistant enterococci in Canada 2009 to 2038"}]},{"@type":"WebSite","@id":"https:\/\/www.cancea.ca\/#website","url":"https:\/\/www.cancea.ca\/","name":"Canadian Centre for Economic Analysis","description":"","publisher":{"@id":"https:\/\/www.cancea.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancea.ca\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-CA"},{"@type":"Organization","@id":"https:\/\/www.cancea.ca\/#organization","name":"Canadian Centre for Economic Analysis","url":"https:\/\/www.cancea.ca\/","logo":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/www.cancea.ca\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancea.ca\/wp-content\/uploads\/2022\/11\/CANCEA-Logo.png","contentUrl":"https:\/\/www.cancea.ca\/wp-content\/uploads\/2022\/11\/CANCEA-Logo.png","width":3679,"height":625,"caption":"Canadian Centre for Economic Analysis"},"image":{"@id":"https:\/\/www.cancea.ca\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.cancea.ca\/#\/schema\/person\/fb2e19aa9612d9bd6408e701abf68b0e","name":"david","image":{"@type":"ImageObject","inLanguage":"en-CA","@id":"https:\/\/www.cancea.ca\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4ac119c7984ffc5e319b73989f8b986a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4ac119c7984ffc5e319b73989f8b986a?s=96&d=mm&r=g","caption":"david"},"sameAs":["https:\/\/beta.cancea.ca"],"url":"https:\/\/www.cancea.ca\/index.php\/author\/david\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cancea.ca\/index.php\/wp-json\/wp\/v2\/posts\/2801"}],"collection":[{"href":"https:\/\/www.cancea.ca\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cancea.ca\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cancea.ca\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cancea.ca\/index.php\/wp-json\/wp\/v2\/comments?post=2801"}],"version-history":[{"count":2,"href":"https:\/\/www.cancea.ca\/index.php\/wp-json\/wp\/v2\/posts\/2801\/revisions"}],"predecessor-version":[{"id":3337,"href":"https:\/\/www.cancea.ca\/index.php\/wp-json\/wp\/v2\/posts\/2801\/revisions\/3337"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancea.ca\/index.php\/wp-json\/wp\/v2\/media\/2802"}],"wp:attachment":[{"href":"https:\/\/www.cancea.ca\/index.php\/wp-json\/wp\/v2\/media?parent=2801"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cancea.ca\/index.php\/wp-json\/wp\/v2\/categories?post=2801"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cancea.ca\/index.php\/wp-json\/wp\/v2\/tags?post=2801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}